pharmaphorum March 20, 2024
A key hurdle in front of the EU reforms to pharma legislation has fallen, after the European Parliament’s Environment, Public Health and Food Safety (ENVI) committee approved a series of amendments to the original draft.
First tabled last year, the wide-ranging regulation has been criticised by the pharma industry, which claims it will have a detrimental effect on Europe’s competitiveness, as well as the life sciences sector and patient care.
Despite amendments designed to address some of industry’s concerns, the European Federation of Pharmaceutical Industries and Associations (EFPIA) is still not happy, saying that, even though “pragmatic improvements” have been made, “the net impact of the proposals will make Europe less competitive and less attractive as a region for researching...
Today's Sponsors
Today's Sponsor